Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oooh ! <light bulb>. They have 60% of the 325 mg patients to draw from. Duh ! Sorry everybody. That’s at least 75 patients and 30% of 525 mg. There’s another 50. Not all of them will try again, tho.
But they do need enough 700 mg patients to have .... uhhh .. statistical power (?) for the trial. And that number would be ... 100 ? Say they are switching 25, then it would take 5 more months of recruitment. To me, that is a disappointment. I may be using bad numbers, please correct me if I’m wrong.
Heck no !; we *should* be much higher ! It’s just that I had previously thought Mono would be completed a year from now. At this time I would say 18 months from now.
I agree Nader gives out timelines, and they are missed and that is really frustrating. But you are double and triple counting delays, IMO. But still mono is getting pushed out. We’ve got to get 100 (?) patients at 700mg. That will take 7 months, maybe 5 months yet to enroll. 12 months to observe, and 1 to organize data and were looking at ... January 2020 to finish ? Ewwww.
Just Google “galectin proteins”. It will be obvious
I sold some of my CYDY to buy another tiny developing bio with a tiny mkt cap that has a product in trials that can also address cancer, NASH, fibrosis, and many other diseases. IMO, Nearly a twin of CYDY except they use .... galectin proteins instead of an antibody. (I’m not promoting, just mentioning similarities)
Its not just patents and expertise Pestell brings .... it’s the FUNDING !
10% a day; that’s all I ask.
Thank you Tony, that is very good to know
Nader said ABOUT 70% and that it could fall (or rise) a little as the trial goes on. The final figure might be 65%. That’s why the 700mg dose is necessary.
Nader will be presenting finalized combo results, right ?
Previously the company said they would submit everything by the end of the year, now they say they won’t have it complete until the first half of 2019. Which often means the second half of 2019.
And they’ve expected an organic uplisting for over a year.....
I don’t understand. Then why did the “rolling” BLA get pushed back 6 months ?
Last chance to buy before the conference call !
Have you ever been involved in a r/s that showed PE in Phase 3 and involving perhaps the leading cancer researcher in the world ? If not, then perhaps CYDY would have been different
I think that’s what Finesand said, but I hope that was a conservative guess.
If buying Pestell’s company and IP will take 70Mill shares wouldn’t that buy itself mean a ~20% dilution and a 20% haircut Wednesday morning ? Hopefully, that will be more than offset by whatever other news contained in Tuesday’s CC.
A couple weeks back someone said GALT was going back to $4. That seems a bit much, but the way the volume is drying up, $5.00 seems quite possible.
You all can make better sense of this than I can.
https://scholar.google.com/scholar?q=aids+related+cancer+ccr5&hl=en&as_sdt=0&as_vis=1&oi=scholart
Perhaps they want to license HIV to BP, so as to fund all these other indications.
Didja see the news on the old stock ? Pestell is now on BOD. Will attract MUCH needed attn. Good thing I kept 2/3’s of my shares.
Awesome ! Thanks for posting. Although I was hoping for a shorter trial time than 18 months.
That June conference calls which now won’t likely be before August ? I no longer am confident there will be one this summer.
Here is a link to 1,300+ research articles on galectin proteins. https://pubs.acs.org/action/doSearch?AllField=galectin
Of course, this is not only company research, but meant to show all of the possibilities that the company *could* get into. Immune regulation, cancer, Pulm Fib, metastatic Breast cancer, melanoma, heart failure, inflammation, mult myeloma, glioblastoma, leukemia, ALS, liver fibrosis .... that’s just the first 50 articles. A good question is, what uses are covered by patent ?
We are past 10, the FDA allowed CYDY to change the protocol to eliminate the placebo arm and allow for a different type of ablation. After 30 days of 10 more patients, the FDA may rule again. We are somewhere in the teens; maybe 11 with CYDY history. Most important info, IMO. Company never gives out that info; I ask repeatedly.
BP could just be not getting it. Like the FDA coming changing the food pyramid to a food plate, still having grains as a large portion of meals. More and more research shows benefits to low carb higher fat, and detriment to high-carb low-fat, yet much of the medical establishment holds onto 40 year old thinking. But if BP ain’t getting it, that could continue until VERY late. Whenever that is.
I didn’t say that. I said that don’t care whether you have one or not.
Yes Tom, you were right about that symbol.
On this volume ? We’re going nowhere. However, I expect news which should change that. But my expectation of such news keeps getting pushed out as company timelines get pushed. Complete combo results, partnership, new trial starting, GvHD decision from FDA, mono interim results ..... these things WILL happen. If you can’t wait, then cut some or all of your immense losses and buy some momentum stock. This is the wrong sector for you. Or if you insist staying long, have a heart attack and die, either way is fine with me.
There is a small company with very promising drugs / biologics, similar to CYDY, who *IS* ready and actively taking steps to sell or license their property. Maybe you should invest partly there so that you would be less unsatisfied (and less annoying) here. Hint, look at galectin proteins.
The $5.7 Mill will pay for general expenses until fall, but what about the CRO bills ? Who knows when they come due.
I should short stocks, because stocks always drop 5% with a day after I purchase them. Uncanny !
How is the development of a subcutaneous or pill form of treatment going ?
Oh, sure ... gap up when I want to buy !
Interesting. This might be a more promising and undervalued company than Cytodyn. CYDY.
YES ! I would have thought management would’ve acted on GvHD already. The company might have a deal in place by the time the trials are nearly complete.
But total shares will go over 500 Mill by the time Mono is funded. That’s $5B. BP will pay that and more for any sort of mono approval. We won’t see any figure like that until well into 2019.
Thanks for that diligent research, chumppunk !
So, would there be a cc after final combo results are done ? I now suspect there won’t be one. We already know one shot of Pro140 reduces viral load by a factor of 40. If that got no market reaction, what would from combo ? There will not be an interim report on the mono trial because they didn’t bother with the interim combo report. I am not deluding myself into thinking there are all these possible deals that might happen cause .... I’ve been thinking that for too long. GvHD protocol revision will still take a long time because it took so long to find the first 10 patients. Despite the change in ablation. With luck and CYDY time projections, the BLA will begin to be submitted in early 2019. I think we will enter 2019 below $1. Paulson still has imo, tens of millions left to sell. Where is the specific kicker / driver ? Hope of a partnership, hope of a buyout, hope of a private placement. I’ve been doing that too long too. Logic seems to drive off my near term optimism. Longer term, I am still optimistic.